Primecap Management CO Neurocrine Biosciences Inc Transaction History

Primecap Management CO

$122 Billion
Q2 2025

A detailed history of Primecap Management CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Primecap Management CO holds 524,040 shares of NBIX stock, worth $71.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

524,040

Previous 382,440 37.03%

Holding current value

$71.6 Million

Previous $42.3 Million 55.72%

% of portfolio

0.05%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$87.54 - $128.18 $12.4 Million - $18.2 Million	141,600 Added 37.03%	524,040 $65.9 Million
Q1 2025 May 09, 2025	SELL	$107.22 - $153.29 $1.21 Million - $1.73 Million	-11,270 Reduced 2.86%	382,440 $42.3 Million
Q4 2024 Feb 10, 2025	SELL	$111.62 - $139.44 $1.15 Million - $1.43 Million	-10,290 Reduced 2.55%	393,710 $53.7 Million
Q3 2024 Nov 08, 2024	SELL	$114.58 - $153.15 $606,128 - $810,163	-5,290 Reduced 1.29%	404,000 $46.5 Million
Q2 2024 Aug 09, 2024	BUY	$130.86 - $143.19 $1.3 Million - $1.42 Million	9,910 Added 2.48%	409,290 $56.3 Million
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $137,832 - $151,933	1,057 Added 0.27%	399,380 $55.1 Million
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $714,699 - $894,536	6,738 Added 1.72%	398,323 $52.5 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $166,885 - $207,852	-1,775 Reduced 0.45%	391,585 $44.1 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $1.94 Million - $2.27 Million	21,620 Added 5.82%	393,360 $37.1 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $34.5 Million - $45.1 Million	366,640 Added 7189.02%	371,740 $37.6 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $544,272 - $648,006	5,100 New	5,100 $609,000

Others Institutions Holding NBIX

# of Institutions

657

Shares Held

101M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Neurocrine Biosciences Inc Transaction History